Patents by Inventor Jason McLellan
Jason McLellan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11919927Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.Type: GrantFiled: April 6, 2023Date of Patent: March 5, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Jason McLellan, Ching-Lin Hsieh, Scott Rush, Nianshuang Wang
-
Patent number: 11890339Abstract: Embodiments of immunogens comprising a recombinant Nipah virus (NiV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant NiV F ectodomain trimer and one or more G ectodomains, a multimer of NiV G ectodomains, and protein nanoparticles comprising the recombinant NiV F ectodomain trimer or an NiV G ectodomain. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject.Type: GrantFiled: August 5, 2019Date of Patent: February 6, 2024Assignees: The United States of Americam as represented by the Secretary, Department of Health and Human Services, Trustees of Dartmouth CollegeInventors: Barney Graham, Rebecca Loomis, Guillaume Stewart-Jones, John Mascola, Jason McLellan
-
Publication number: 20230357327Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.Type: ApplicationFiled: April 6, 2023Publication date: November 9, 2023Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Jason MCLELLAN, Ching-Lin HSIEH, Scott RUSH, Nianshuang WANG
-
Publication number: 20230348571Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.Type: ApplicationFiled: April 6, 2021Publication date: November 2, 2023Inventors: Ivelin Stefanov Georgiev, Andrea R. Shiakolas, Kevin J. Kramer, James E. Crowe, Jr., Robert Carnahan, Nianshuang Wang, Daniel Wrapp, Jason McLellan
-
Publication number: 20230287055Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: ApplicationFiled: January 31, 2023Publication date: September 14, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Publication number: 20230277653Abstract: Provided herein are engineered protein comprising stabilized coronavirus S protein ectodomains, such as stabilized SARS-CoV-2 S protein ectodomains. In some aspects, the engineered S protein ectodomains exhibit enhanced antigenicity. Methods are also provided for use of the engineered S protein ectodomains as diagnostics, in screening platforms, and/or in vaccine compositions.Type: ApplicationFiled: December 2, 2022Publication date: September 7, 2023Inventors: Jason MCLELLAN, Ching-Lin HSIEH
-
Publication number: 20230242594Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.Type: ApplicationFiled: May 28, 2021Publication date: August 3, 2023Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGEInventors: Jason MCLELLAN, Jennifer MAYNARD, Andrea CHASSE, Ilya FINKELSTEIN, Mohammad JAVANMARDI, Jeffrey SCHAUB, Hung-Che KUO, Chia-Wei CHOU, Jory GOLDSMITH, Christy HJORTH, Ching-Lin HSIEH, Patrick BYRNE, Nicole JOHNSON, Nianshuang WANG, Daniel WRAPP
-
Publication number: 20230227537Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.Type: ApplicationFiled: February 5, 2021Publication date: July 20, 2023Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
-
Publication number: 20230113170Abstract: SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.Type: ApplicationFiled: February 11, 2021Publication date: April 13, 2023Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Board of Regents, The University of Texas System, Trustees of Dartmouth CollegeInventors: Barney Graham, Kizzmekia Corbett, Olubukola Abiona, Geoffrey Hutchinson, Jason McLellan, Daniel Wrapp, Nianshuang Wang
-
Patent number: 11591372Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: GrantFiled: May 18, 2020Date of Patent: February 28, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Patent number: 11248039Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: September 10, 2019Date of Patent: February 15, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Publication number: 20210299242Abstract: Embodiments of immunogens comprising a recombinant Nipah virus (NiV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant NiV F ectodomain trimer and one or more G ectodomains, a multimer of NiV G ectodomains, and protein nanoparticles comprising the recombinant NiV F ectodomain trimer or an NiV G ectodomain. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject.Type: ApplicationFiled: August 5, 2019Publication date: September 30, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Trustees of Dartmouth CollegeInventors: Barney Graham, Rebecca Loomis, Guillaume Stewart-Jones, John Mascola, Jason McLellan
-
Publication number: 20210275664Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: ApplicationFiled: March 8, 2021Publication date: September 9, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Patent number: 10960070Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: GrantFiled: October 25, 2017Date of Patent: March 30, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Patent number: 10858400Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.Type: GrantFiled: June 26, 2017Date of Patent: December 8, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Baoshan Zhang, Tongqing Zhou, Michael Gordon Joyce, Yongping Yang
-
Publication number: 20200277338Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: ApplicationFiled: May 18, 2020Publication date: September 3, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Patent number: 10654898Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: GrantFiled: January 20, 2016Date of Patent: May 19, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human SericesInventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Publication number: 20200102374Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: ApplicationFiled: September 10, 2019Publication date: April 2, 2020Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
-
Publication number: 20200061185Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: ApplicationFiled: October 25, 2017Publication date: February 27, 2020Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Patent number: 10501528Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: June 20, 2016Date of Patent: December 10, 2019Assignees: V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman